 - has abnormal blood coagulation due to primary disease or due to treatment with anticoagulants warfarinphenprocoumon, unfractionated heparin, low- molecular heparin, with the clinical blood tests INR and APTT, outside the intervals given below, at the time of inclusion. Patients with unfractionated Heparin 100 IEml used as a catheter lock, do not need to have APTT tested before enrollment. Patients treated with Low-Molecular Heparin, needs control of INR, thrombocytes and plasma-antifactor Xa, and If the patient has increased bleeding risk judge by disease and clinical blood tests, the patient can t be included in the trial. INR 0.9-3.0 warfarin phenprocoumon APTT needs to be in the range 25-100 seconds Unfractionated Heparin treatment Plasma-antifactor Xa outside recommended intervals pro.medicin.dk, which are dependent on administration form and number of daily administrations . Thrombocytes 100- 600 x109L 